ACT: Avastin and Chemoterapy followed by Avastin alone or in combination with Tarceva for the treatment of metatstatic colorectal cancer - ACT
- Conditions
- Patients with previously untreated meastatic colorectal carcinoma.
- Registration Number
- EUCTR2006-002295-18-SE
- Lead Sponsor
- niversity Hospital Lund, Dept of Oncology, Clinical Trial Unit
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 240
Untreated metastatic colorectal carcinoma
Age = 18 years
Measurable disease according to Response Evaluation Criteria in solid Tumors (RECIST) criteria
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Life expectancy more than 3 months.
Adequate haematological, renal and liver function
Blood sample and paraffin embedded tumour tissue for translational research
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years)
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years)
F.1.3.1 Number of subjects for this age range
Adjuvant therapy within 6 months
Central nervous system (CNS) metastases
Clinically significant atherosclerotic vascular disease
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method